The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia

被引:0
作者
Tengiz Tsertsvadze
Lali Sharvadze
Nikoloz Chkhartishvili
Lela Dzigua
Marine Karchava
Lana Gatserelia
Akaki Abutidze
Kenrad E. Nelson
机构
[1] Ivane Javakhishvili Tbilisi State University,Faculty of Medicine
[2] AIDS and Clinical Immunology Research Center,Infectious Diseases
[3] Georgian-French Joint Hepatology Clinic ‘Hepa’,Bloomberg School of Public Health
[4] Johns Hopkins University,undefined
来源
Virology Journal | / 13卷
关键词
HCV; Natural history; Seroconversion; Transitory;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 173 条
[1]  
Mohd Hanafiah K(2013)Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence Hepatology 57 1333-1342
[2]  
Groeger J(2012)Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2095-2128
[3]  
Flaxman AD(2013)Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol 10 553-562
[4]  
Wiersma ST(2013)Global control of hepatitis C: where challenge meets opportunity Nat Med 19 850-858
[5]  
Lozano R(2012)The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med 156 271-278
[6]  
Naghavi M(2014)Direct-acting antiviral agents and the path to interferon independence Clin Gastroenterol Hepatol 12 728-737
[7]  
Foreman K(2013)Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals Hepatology 58 1598-1609
[8]  
Lim S(2014)The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis PLoS One 9 e101554-380
[9]  
Shibuya K(2013)Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges Futur Virol 8 371-414
[10]  
Aboyans V(2012)Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine Lancet Infect Dis 12 408-298